Paliperidone API Receives Marketing Approval
March 18, 2026
Source: drugdu
31
PKU HealthCare announced on the evening of March 17 that it recently received the " Chemical Raw Materials" certificate issued by the National Medical Products Administration. The drug marketing application approval notice was issued, and the submitted product "paliperidone (packaging specifications: 1kg/bag, 5kg/bag, 10kg/bag)" was approved for registration after review, meeting the relevant requirements for drug registration.
Data shows that paliperidone is the main active metabolite of risperidone. It is a second-generation antipsychotic drug with strong control effects, high affinity, tolerability and efficacy. It is mainly used to treat schizophrenia in adults and adolescents aged 12-17 (weight ≥29Kg).
PKU HealthCare stated that paliperidone raw material The approval will help the company further promote its "raw material and formulation integration" strategy, create synergies with formulation products, enhance its competitiveness in production cost control and supply chain stability, and have a positive effect on the company's future performance.
https://finance.eastmoney.com/a/202603173674705264.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Subsidiary obtains registration certificate for antidepressant drug March 18, 2026
- Fosun Pharma’s subsidiary, Junji Health, has received clinical trial approval from the National Medical Products Administration for its LBP-ShC4 product. March 18, 2026
- A world first! my country achieves regenerated islet transplantation, opening a new path for diabetes treatment. March 18, 2026
- How long until the first generic version? March 18, 2026
- Haizheng Pharmaceutical’s Haibomaibu Atorvastatin Calcium Tablets Approved for Clinical Trials March 18, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
